In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Esperion (ESPR). The company’s shares opened today at $50.09.
Archila noted:
“We are reiterating our Buy rating on ESPR shares after today’s investor day where the company provided some additional color on its commercial plans for bempedoic acid (BPA)/combo. While there was not much new discussed at the investor day, we continue to view BPA/combo as meaningfully de-risked from a clinical/regulatory perspective with a high probability of approval (POS: 85%). Investor focus has shifted to BPA/combo’s commercial viability and management/KOLs spent most of the time at the investor day addressing aspects of patient targeting, payer strategy and where BPA/combo will ultimately fit in the LDL-C lowering treatment algorithm.”
According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -9.8% and a 33.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Principia Biopharma Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $69.13.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $87.38 million. In comparison, last year the company had a GAAP net loss of $46.13 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).